

**Pubblicazioni correlate all'attività dell'Ambulatorio  
"Patologia Focale del Fegato"  
(2010-2020)**

**2010**

1. F. Trevisani, M. Frigerio, V. Santi, A. Grignaschi, M. Bernardi. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. *Digest. Liver Dis.*, 42: 341-7, 2010. \*
2. E.G. Giannini, G. Bodini, M. Corbo, D. Risso, V. Savarino, M.A. Di Nolfo, P. Del Poggio, L. Benvegnù, F. Farinati, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITALI.CA.) group. Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma. *Alim. Pharmacol. Ther.*, 31; 493-501, 2010. \*
3. F. Mirici-Cappa, A. Gramenzi, V. Santi, A. Zambruni, A. Di Micoli, M. Frigerio, F. Maraldi, M.A. Di Nolfo, P. Del Poggio, L. Benvegnù, G. Rapaccini, F. Farinati, M. Zoli, F. Borzio, E. G. Giannini, E. Caturelli, M. Bernardi, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA.) group. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicenter experience. *Gut*, 59: 387-396, 2010. \*
4. E. G. Giannini, V. Savarino, D. Risso, M. A. Di Nolfo, P. Del Poggio, L. Benvegnù, F. Farinati, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA.) group. Transarterial chemoembolization in Child-Pugh class B patients with HCC: between the devil and the deep blue sea. *Liver Int.*, 30, 923-924, 2010. \*
5. V. Santi, F. Trevisani, A. Gramenzi, A. Grignaschi, F. Mirici-Cappa, P. Del Poggio, M. A. Di Nolfo, L. Benvegnù, F. Farinati, M. Zoli, E. G. Giannini, F. Borzio, E. Caturelli, M. Chiaramonte, M. Bernardi, for the Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J. Hepatol.*, 53: 291-7, 2010. \*

**2011**

6. E.G. Giannini, V. Savarino, D. Risso, M.A. Di Nolfo, P. Del Poggio, L. Benvegnù, F. Farinati, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA.) group. Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study. *Liver Int.*, 31: 192-6, 2011. \*
7. E.G. Giannini, F. Farinati, F. Trevisani. Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead. *Hepatology*, 54: 376-377, 2011 (lettera). \*
8. R. Golfieri, M. Renzulli, V. Lucidi, B. Corcioni, F. Trevisani, L. Bolondi. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small ( $\leq 2$  cm) HCC in cirrhosis. *Eur. Radiol.*, 21: 1233-1242, 2011.

9. T. Stroffolini, F. Trevisani, G. Pinzello, F. Brunello, M. A. Tommasini, M. Iavarone, V. Di Marco, F. Farinati, P. Del Poggio, F. Borzio, M. Borzio, E. Caturelli, M. A. Di Nolfo, G. B. Gaeta. Changing etiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. *Digest. Dis. Sci.*, 43: 875-80, 2011. \*
10. A. Vitale, R.R. Morales, G. Zanusi, P. Burra, F. Farinati, P. Del Poggio, G. Rapaccini, M.A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E.G. Giannini, E. Caturelli, M. Chiaramonte, F. Trevisani, U. Cillo, on behalf of the ITA.LI.CA study group. Barcelona Clinic Liver Cancer staging and transplant survival benefit in hepatocellular carcinoma patients: a multicentre cohort study. *Lancet Oncol.*, 12: 654-62, 2011. *\*Articolo vincitore del PREMIO AISF per la migliore pubblicazione italiana dell'anno 2011 in campo epatologico.*
11. J.M. Lee, F. Trevisani, V. Vilgrain, C. Wald. Imaging diagnosis and staging of hepatocellular carcinoma. *Liver Transplant*, 17: S34-S43, 2011. \*
12. M. Ravaioli, A. Cucchetti, M. Cescon, F. Piscaglia, G. Ercolani, F. Trevisani, A.D. Pinna. Systematic review of outcome of downstaging hepatocellular carcinoma before liver transplantation in patients outside the Milan criteria. *Brit. J. Surg.*, 98: 673-5, 2011 (lettera).

## 2012

13. F. Farinati, A. Giacomini, V. Vanin, A. Sergio, P. Burra, U. Cillo, M. A. Di Nolfo, P. Del Poggio, L. Benvegnù, M. Zoli, F. Borzio, E. G. Giannini, E. Caturelli, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicenter experience in Italy. *Eur. J. Gastroenterol. Hepatol.*;24:195-202, 2012. \*
14. V. Santi, D. Buccione, A. Di Micoli, G. Fatti, M. Frigerio, F. Farinati, P. Del Poggio, G. Rapaccini, M.A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E.G. Giannini, E. Caturelli, M. Chiaramonte, M. Bernardi, F. Trevisani, for the ITA.LI.CA Group. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. *J. Hepatol.*, 56: 397-405, 2012. \*
15. P.A. Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gores, B. Langer, A. Perrier; on behalf of the OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. *Lancet Oncol.*, 13: e11-22, 2012. \*
16. A. Cucchetti, F. Trevisani, M. Cescon, G. Ercolani, F. Farinati, P. Del Poggio, G. Rapaccini, M.A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E. G. Giannini, E. Caturelli, M. Chiaramonte, A. D. Pinna, for the ITA.LI.CA Group. Cost-effectiveness of semiannual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. *J. Hepatol.*, 56; 1089-96, 2012. \*
17. F. Farinati, A. Giacomini, V. Vanin, E. Giannini, F. Trevisani, for the ITA.LI.CA group. TACE treatment in hepatocellular carcinoma: what should we do now? *J. Hepatol.*, 57: 221-2, 2012 (lettera). \*
18. A. Cucchetti, M. Cescon, F. Trevisani, M.C. Morelli, G. Ercolani, S. Pellegrini, V. Erroi, E. Bigonci, A. D. Pinna. What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? *Digest. Liver Dis.*, 44: 523-9, 2012. \*
19. D. Buccione, G. Fatti, A. Gallotta, E. Loggi, R. Di Donato, L. Testa, C. Saitta, V. Erroi, M. Frigerio, V. Fazio, A. Picciotto, A. Biasiolo, F. Degos, P. Pontisso, G. Raimondo, F. Trevisani. Serum SCCA-

IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. *Open J. Gastroenterol.*, 2; 56-61, 2012.

20. J. M.. Llovet, C.E.A. Peña, C.D. Lathia, M. Shan, G. Meinhardt, J. Bruix, on behalf of the SHARP Investigators Study Group. Plasma Biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. *Clin. Cancer Res.*; 18: 2290-300, 2012. \*
21. E.G. Giannini, V. Erroi, F. Trevisani. Effectiveness of alpha-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? *Expert Rev. Gastroenterol. Hepatol.*, 6:441-444, 2012 (lettera). \*
22. E.G. Giannini, S. Marengo, G. Borgonovo, V. Savarino, F. Farinati, P. Del Poggio, G. L. Rapaccini, M. A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. *Hepatology*; 56: 1371-1379, 2012. \*
23. E.G. Giannini, S. Marengo G. Borgonovo, V. Savarino, F. Farinati, P. Del Poggio, G. L. Rapaccini, M. A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience. *Am. J. Gastroenterol.*; 107: 1588-9, 2012. \*
24. A.Cucchetti, M. Cescon, F. Trevisani, A.D. Pinna. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. *World J. Gastroenterol.*;18: 6398-408, 2012. \*

## 2013

25. E.G. Giannini, S Marengo, L. Bruzzone, V. Savarino, F. Farinati, P. Del Poggio, G. L. Rapaccini, M. A. Di Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Hepatocellular carcinoma in patients without cirrhosis in Italy. *Dig. Liver Dis*, 45:164-9, 2013 (doi: 10.1016/j.dld.2012.08.018). \*
26. Gramenzi, S. Tedeschi, M.C. Cantarini, V. Erroi, F. Tumietto, L. Attard, L. Calza, F. G. Foschi, P. Caraceni, M. Pavoni, A. Cucchetti, M. Bernardi, P.L. Viale, G. Verucchi, F. Trevisani. Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. *Dig. Liver Dis.*; 45:516-22, 2013. \*
27. R. Golfieri, M. Renzulli, C. Mosconi, L. Forlani, E. Giampalma, F. Piscaglia, F. Trevisani, L. Bolondi, for the BLOG (Bologna Liver Oncology Group). HCC responding to superselective transarterial chemoembolization: an issue of nodule dimensions? *J. Vasc. Interv. Radiol.*, 24: 509-17, 2013. \*
28. E.G. Giannini, F. Farinati, F. Trevisani. Adequate interval for hepatocellular carcinoma surveillance. *Am. J. Gastroenterol.*, 108:1174, 2013 (doi: 10.1038/ajg.2013.133) (lettera). \*
29. Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. *Dig. Liver Dis.*; 45: 712-23. 2013.\*
30. E.G. Giannini, F. Trevisani. Surveillance for hepatocellular carcinoma: just to do it!. *Am. J. Gastroenterol.*, 108:1013-4, 2013 (doi: 10.1038/ajg.2013.98) (lettera). \*

31. E.G. Giannini, V. Savarino, F. Farinati, F. Ciccarese, G. L. Rapaccini, M. Di Marco, L. Benvegnù, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. *Liver Int.*; 33:1594-600, 2013 (doi: 10.1111/liv.12199). \*
32. N. Cazzagon, F. Trevisani, G. Maddalo, A. Giacomini, V. Vanin, C. Pozzan, P.D. Poggio, G. Rapaccini, A.M. Nolfo, L. Benvegnù, M. Zoli, F. Borzio, E.G. Giannini, E. Caturelli, M. Chiaramonte, F.G. Foschi, G. Cabibbo, M. Felder, F. Ciccarese, G. Missale, G.S. Baroni, F. Morisco, A. Pecorelli, F. Farinati; Italian Liver Cancer (ITA.LI.CA) Group. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. *Liver Int.*; 33 :1420-7, 2013. \*
33. E.G. Giannini, A. Cucchetti, V. Erroi, F. Garuti, F. Odaldi, F. Trevisani. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? *World J. Gastroenterol.*; 19: 8808-21, 2013 (doi: 10.1038/ajg.2013.98). \*  
*Articolo selezionato dal gruppo Baishideng Publishing Group (BPG) per l'inserimento nell'open access book "World Clinical Gastroenterology (WCG)" 2013 (sito web: <http://www.wjgnet.com/bpg/E-books.htm>).*
34. G. Brandi, F. de Rosa, V. Agostini, S. Di Girolamo, P. Andreone, L. Bolondi, C. Serra, C. Sama, R. Golfieri, A. Gramenzi, A. Cucchetti, A. D. Pinna, F. Trevisani, G. Biasco, and the Italian Liver Cancer (ITA.LI.CA) group. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. *The Oncologist*; 18:1256-7, 2013 (doi: 10.1634/theoncologist.2013-0093). \*

## 2014

35. Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. *Semin Oncol.*;41:406-414, 2014 (doi: 10.1053/j.seminoncol.2014.04.002).
36. Giannini EG, Trevisani F. Accuracy of  $\alpha$ -fetoprotein measurement in detection of hepatocellular carcinoma - one more nail in the coffin. *Clin Gastroenterol Hepatol.*; 12:2138-9, 2014 (doi: 10.1016/j.cgh.2014.07.006).
37. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F; PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. *Br J Cancer.*; 111: 255-64, 2014 (doi: 10.1038/bjc.2014.199).
38. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Low alpha-fetoprotein HCC and the role of GGTP. *Int J Biol Markers*; 29:e395-402, 2014 (doi: 10.5301/jbm.5000092).
39. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Ludovico Rapaccini G, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. *Semin Oncol.*; 41: 252-8, 2014 (doi: 10.1053/j.seminoncol.2014.03.006).

40. Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. *Cancer.*; 120: 2150-7, 2014 (doi: 10.1002/cncr.28706).
41. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Giannini EG, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Baroni GS, Virdone R, Bernardi M, Pinna AD; Italian Liver Cancer Group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. *J Hepatol.*; 61: 333-41, 2014 (doi:10.1016/j.jhep.2014.03.037).
42. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiamonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol.*;12: 1927-33.e2, 2014 (doi:10.1016/j.cgh.2014.02.025).
43. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiamonte M, Trevisani F; Italian Liver Cancer Group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. *Int J Biol Markers*; 29: e215-23, 2014. (doi: 10.5301/jbm.5000064).
44. Giannini EG, Trevisani F. Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. *Hepatology*; 60: 1446-7, 2014 (doi: 10.1002/hep.27008).

## 2015

45. F. Farinati V, Vanin, A, Giacomini, C, Pozzan, U, Cillo, A, Vitale, A.M, Nolfo, P, Del Poggio, L, Benvegnù, G, Rapaccini, M, Zoli, F, Borzio, E.G, Giannini, E, Caturelli, F. Trevisani; The Italian Liver Cancer (ITA.LI.CA) group. BCLC-B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. *Liver Int.*; 35: 223-31, 2015 (doi: 10.1111/liv.12649). \*
46. E.G. Giannini, F. Farinati, F. Ciccarese, A. Pecorelli, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. *Hepatology*; 61:184-90, 2015 (doi: 10.1002/hep.27443) . \*  
*Articolo vincitore del PREMIO AISF per la migliore pubblicazione italiana dell'anno 2015 in campo epatologico.*
47. M. Biselli, F. Conti, A. Gramenzi, M. Frigerio, A. Cucchetti, G. Fatti, M. D'Angelo, M. Dall'Agata, E.G. Giannini, F. Farinati, F. Ciccarese, P. Andreone, M. Bernardi, F. Trevisani. A new approach to the use of  $\alpha$ -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. *Br J Cancer.*; 112: 69-76, 2015 (doi: 10.1038/bjc.2014.536). \*
48. L. Bolondi, A. Craxi, F. Trevisani, B. Daniele, G. G. Di Costanzo, S. Fagioli, C. Cammà, P. Bruzzi, R. Danesi, F. Spandonaro, C. Boni, A. Santoro, M. Colombo. Refining sorafenib therapy: lessons from clinical practice. *Future Oncol.*; 11: 449-65, 2015. \*
49. Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group).

- Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. *Liver Int.*; 35: 1036-47, 2015 (doi:10.1111/liv.12574).
50. E.G. Giannini, F. Trevisani. Screening for hepatocellular carcinoma in chronic liver disease. *Ann. Int. Med.*;162: 239-40, 2015 (doi: 10.7326/L15-5049-2). \*
  51. A Vitale, P Burra, AC Frigo, F. Trevisani, F Farinati, G Spolverato, M Volk, EG Giannini, F Ciccarese, F Piscaglia, GL Rapaccini, M Di Marco, E Caturelli, M Zoli, F Borzio, G Cabibbo, M Felder, A Gasbarrini, R Sacco, FG Foschi, G Missale, F Morisco, GL Svegliati Baroni, R U Virdone, Cillo; Italian Liver Cancer (ITA.LI.CA) group. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. *J. Hepatol.*; 62: 617-24, 2015 (doi: 10.1016/j.jhep.2014.10.037). \*
  52. F. Trevisani, F. Garuti, A. Cucchetti, B. Lenzi, M. Bernardi. De novo hepatocellular carcinoma of liver allograft: a neglected issue. *Cancer Letters*; 357: 47-54; 2015 (doi: 10.1016/j.canlet.2014.11.032).\*
  53. A. Gramenzi, C. Pettinato, A. Cappelli, C. Mosconi, R. Golfieri, F. Trevisani. Reply to: "Sorafenib or <sup>90</sup>Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?" *Liver Int.*; 35: 1780-1, 2015 (doi: 10.1111/liv.12823) (lettera). \*
  54. A. Vitale, F. Farinati, P. Burra, F. Trevisani, E.G. Giannini, F. Ciccarese F. Piscaglia, GL. Rapaccini L, M. Di Marco, E. Caturelli, Zoli M, F. Borzio, G. Cabibbo, M. Felder, R. Sacco, F. Morisco, G. Missale, F.G. Foschi, A. Gasbarrini, G.S. Baroni, R. Virdone, M. Chiaramonte, G. Spolverato, U. Cillo; Italian Liver Cancer (ITA.LI.CA) group. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the Alpha-Fetoprotein Model as a survival predictor. *Liver Transpl.*; 21: 1250-8, 2015 (doi: 10.1002/lt.24214). \*
  55. R. Golfieri, C. Mosconi, A. Capelli, E. Gianpalma, M.C. Galaverni, C. Pettinato, M. Renzulli, F. Monari, B. Angelelli, P. Pini, E. Terzi, S. Ascanio, G. Garzillo, F. Piscaglia, L. Bolondi, F. Trevisani. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. *Future Oncol.*;11: 3133-42, 2015 (doi: 10.2217/fon.15.267). \*
  56. R. Sacco, V. Mismas, A. Granito, G. Musettini, G. Masi, C. Caparello, C. Vivaldi, M. Felder, G. Bresci, L. Fornaro, for the Italian Liver Cancer (ITA.LI.CA) group\*. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. *Int J Biol Markers*; 30 (1): e65-e72, 2015 (doi: 10.5301/jbm.5000117). \*

## 2016

57. L. Bucci, F. Garuti, V. Camelli, B. Lenzi, F. Farinati, E. Giannini, F. Ciccarese, F. Piscaglia, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R.; Sacco, M. Maida, M. Felder, F. Morisco, A. Gasbarrini, S. Gemini, F.G. Foschi, G. Missale, A. Masotto, A. Affronti, M. Bernardi, F. Trevisani. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome *Alim. Pharmacol. Ther.*;43: 385-99, 2016 (doi: 10.1111/apt.13485). \*

58. E.G. Giannini, A. Moscatelli, G. Pellegatta, A. Vitale, F. Farinati, F. Ciccarese, F. Piscaglia, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, G. Cabibbo, M. Felder, R.o Sacco, F. Morisco, G. Missale, F.G. Foschi, A. Gasbarrini, G. Svegliati Baroni, R Virdone, A. Masotto, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Application of the intermediate stage sub-classification to patients with untreated hepatocellular carcinoma. *Am. J. Gastroenterol.*; 111: 70-7; 2016 (doi: 10.1038/ajg.2015.389). \*
59. F. Piscaglia, G. Svegliati-Baroni, A. Barchetti, A. Pecorelli, Marinelli, C. Tiribelli, S. Bellentani, on behalf of the HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic liver disease (NAFLD): a multicenter prospective study. *Hepatology*; 63: 827-38, 2016 (doi: 10.1002/hep.28368). \*
60. A. Cucchetti, F. Trevisani, L. Bucci, M. Ravaioli, F. Farinati, E. G. Giannini, F. Ciccarese, F. Piscaglia, G. L. Rapaccini, M. Di Marco, E. Caturelli<sup>††</sup>, M. Zoli\*, F. Borzio, R. Sacco, M. Maida, M. Felder, F. Morisco, A. Gasbarrini, S. Gemini, F. G. Foschi, G. Missale, A. Masotto, A. Affronti, M. Bernardi, A. D. Pinna, for the Italian Liver Cancer (ITA.LI.CA) group. Years of life that could be saved from prevention of hepatocellular carcinoma. *Alim. Pharmacol. Ther.*; 43: 814-24, 2016 (doi:10.1111/apt.13554). \*
61. A. Cucchetti, F. Garuti, A.D. Pinna, F. Trevisani. Length time bias in surveillance for hepatocellular carcinoma diagnosis and how to avoid it. *Hepatol. Res.*; 46: 1275-1280, 2016 (doi: 10.1111/hepr.12672). \*
62. M. Bitzer, M. Horger, E. G. Giannini, T. M. Ganten, M. A. Woerns, J. T. Siveke, M. M. Dollinger, G. Gerken, M. E. Scheulen, H. Wege, V. Zagonel<sup>1</sup>, U. Cillo<sup>10</sup>, F. Trevisani, A. Santoro, V.o Montesarchio, N. P. Malek, J. Holzapfel, T. Herz, A. S. Ammendola, S. Pegoraro, B. Hauns, A. Mais, U. M. Lauer, S. W. Henning, B. Hentsch. Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. *J. Hepatol.*; 65: 280–288, 2016 (doi: 10.1016/j.jhep.2016.02.043) (**con Editoriale**). \*
63. F. Trevisani, R. Golfieri. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: where are we now? (Editoriale). *Hepatology* 64: 23-5 (doi: 10.1002/hep.28554) (Editoriale) 2016. \*
64. F. Farinati, A. Vitale, G. Spolverato, T.M. Pawlik, T.L. Huo, Y.H. Lee, A.C. Frigo, A. Giacomini, E.G. Giannini, F. Ciccarese, F. Piscaglia, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, G. Cabibbo, M. Felder, R. Sacco, F. Morisco, E. Biasini, F.G. Foschi, A. Gasbarrini, G. Svegliati Baroni, R. Virdone, A. Masotto, F. Trevisani, U. Cillo; ITA.LI.CA study group. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. *PLoS Med.*; 26; 13(4): e1002006, 2016 (doi: 10.1371/journal.pmed.1002006) (**con Editoriale**).\*
65. A. Cucchetti, F. Trevisani, A. Cappelli, C. Mosconi, M. Renzulli, A.D. Pinna, R. Golfieri. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemoembolization for hepatocellular carcinoma. *Dig. Liver Dis.*; 48: 798-805, 2016 (doi: 10.1016/j.dld.2016.03.031).\*
66. F. Garuti, V. Camelli<sup>1</sup>, L. Spinardi, L. Bucci, F. Trevisani. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. *Tumori*, 11; 102 (Suppl. 2), 2016 (doi: 10.5301/tj.5000504). \*
67. C. Mosconi, A. Gramenzi, S. Ascanio, A. Cappelli, M. Renzulli, C. Pettinato, G. Brandi, F. Monari, A. Cucchetti, F. Trevisani, R. Golfieri. Yttrium-90 radioembolization for unresectable/recurrent

intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. *Br. J. Cancer*; 115: 297-302, 2016 (doi: 10.1038/bjc.2016.191) [Epub ahead of print]. \*

68. M. Kudo, F. Trevisani, G.K. Abu-Alfa, L. Rimassa. Hepatocellular Carcinoma: Therapeutic guidelines and medical treatment. *Liver Cancer*; 6:16-26, 2016 (doi: 10.1159/000443567). \*
69. L. Bucci, F. Garuti, B. Lenzi, A. Pecorelli, F. Farinati, E. G. Giannini, A. Granito, F. Ciccarese, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, C. Cammà, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati-Baroni, F. Giuseppe Foschi, G. Missale, A. Masotto, G. Nardone, A. Colecchia, M. Bernardi, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. *Liver Int.*, 37: 259-270 2016 (doi: 10.1111/liv.13204). \*
70. A. Pecorelli, B. Lenzi, A. Gramenzi, F. Garuti, F. Farinati, E. G. Giannini, F. Ciccarese, F. Piscaglia, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, G. Cabibbo, M. Felder, F. Morisco, A. Gasbarrini, G. Svegliati Baroni, F. G. Foschi, E. Biasini, A. Masotto, R. Virdone, M. Bernardi, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Curative therapies are superior to transarterial chemoembolization for intermediate stage hepatocellular carcinoma. *Liver Int.*, 37: 423-433, 2016 (doi: 10.1111/liv.13242). \*
71. F. Trevisani, L. Bucci, F. Garuti. Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma? *Hepatology*; 64: 2257-2258 (doi: 10.1002/hep.28804), 2016 (lettera).\*
72. Cucchetti A, R. Golfieri, F. Trevisani, on the behalf of the Italian Liver Cancer (ITA.LI.CA). Group. Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-foetoprotein levels. *Liver Int.*; 36: 1877, 2016 (doi: 10.1111/liv.13196) (lettera). \*
73. B. I. Carr, V. Guerra, E. G. Giannini<sup>3</sup>, F. Farinati, F. Ciccarese, G. L. Rapaccini, M. Di Marco, L. Benvegnù, M. Zoli, F. Borzio, E. Caturelli, A. Masotto, F. Trevisani. A Liver Index and its relationship to indices of HCC aggressiveness. *J. Integr. Oncol.*, 5: 178-184, 2016 (doi:10.4172/2329-6771.1000178).

## 2017

74. S. Petta, G. Cabibbo, M. Barbara, S. Attardo, L. Bucci, F. Farinati, E.G. Giannini, F. Tovoli, F. Ciccarese, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati-Baroni, F.G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, M. Persico, V. Boccaccio, A. Craxì, S. Bruno, F. Trevisani, C. Cammà; Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. *Alim. Pharmacol. Ther.* ; 45: 160-168, 2017 (doi: 10.1111/apt.138212016). \*
75. G. Cabibbo, S. Petta, M. Barbara, G. Missale, R. Virdone, E. Caturelli, F. Piscaglia, F. Morisco, A. Colecchia, F. Farinati, E. G. Giannini, F. Trevisani, A. Craxi, M. Colombo, C. Cammà, on behalf of the ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. *Liver Int.* 37: 1157-1166, 2017, (doi: 10.1111/liv.13357). \*
76. G. Cabibbo, S. Petta, M. Barbara, S. Attardo, L. Bucci, F. Farinati, E. G. Giannini, G. Negrini, F. Ciccarese, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, R. Virdone, F.



Marra, A. Mega, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati-Baroni, F. G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, M. Persico, A. Craxì, F. Trevisani, C. Cammà, for the Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. *J. Hepatol.*; 67: 65-71, 2017 (doi: 10.1016/j.jhep.2017.01.033). \*

## 2018

77. A. Cucchetti, G. D'Amico, F. Trevisani, M.C. Morelli, A. Vitale, A.D.Pinna, M. Cescon; from the Special Interest Group on Hepatocellular carcinoma and new anti HCV therapies of the Italian Association for the Study of the Liver (AISF). Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. *Dig. Liver Dis.*; 50: 156-162, 2018 (doi: 10.1016/j.dld.2017.10.004). \*
78. E. G. Giannini, L. Bucci, F. Garuti, M. Brunacci, B. Lenzi, M. Valente, E. Caturelli, G. Cabibbo, F. Piscaglia, R. Virdone, M. Felder, F. Ciccarese, F. G. Foschi, R. Sacco, G. Svegliati Baroni, F. Farinati, G. L. Rapaccini, A. Olivani, A. Gasbarrini, M. Di Marco, F. Morisco, M. Zoli, A. Masotto, F. Borzio, L. Benvegnù, F. Marra, A. Colecchia, G. Nardone, M. Bernardi, F. Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. *Hepatology* 2018; 67: 1784-1796 (doi: 10.1002/hep.29668). \*
79. F. Trevisani, G. Brandi, F. Garuti, M.A. Barbera, R. Tortora, A. Casadei Gardini, A. Granito, F. Tovoli, S. De Lorenzo, A.L. Inghilesi, F.G. Foschi, M. Bernardi, F. Marra R. Sacco, G.G. Di Costanzo. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. *J. Cancer Res. Clin.Oncol.*; 144: 403-414, 2018 (doi: 10.1007/s00432-017-2556-6). \*
80. A. Pecorelli, B. Lenzi, F. Trevisani; Italian Liver Cancer (ITA.LI.CA) group. Response to: Intermediate stage treatment: Is TACE enough? *Liver Int.*; 38:188-189, 2018 (doi: 10.1111/liv.13624) (Lettera). \*
81. A. Vitale, Q. Lai, F. Farinati, L. Bucci, E.G. Giannini, L. Napoli, F. Ciccarese, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, G. Cabibbo, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, Gasbarrini, G. Svegliati-Baroni, F.G. Foschi, G. Missale, A. Masotto, G. Nardone, A. Colecchia, M. Bernardi, F. Trevisani, T.M. Pawlik; Italian Liver Cancer (ITA.LI.CA) group. Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from ITA.LI.CA Study Group. *J. Gastrointest. Surg.*; 22: 859-871, 2018 (doi: 10.1007/s11605-018-3688-y (doi: 10.1007/s11605-018-3688-y)). \*
82. F. Morisco, M. Guarino, M.R. Valvano, F. Auriemma, F. Farinati, E.G. Giannini, F. Ciccarese, F. Tovoli, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, G. Cabibbo, M. Felder, L. Benvegnù, A. Gasbarrini, G. Svegliati Baroni, F.G. Foschi, E. Biasini, A. Masotto, R. Virdone, F. Marra, N. Caporaso, F. Trevisani; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. *Liver Int.*, 38: 2028-2039, 2018 (doi: 10.1111/liv.13877). \*
83. Carr BI, Giannelli G, Guerra V, Giannini EG, Farinati F, Rapaccini GL, Marco MD, Zoli M, Caturelli E, Masotto A, Virdone R, Sacco R, Trevisani F. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. *Int. J. Biol. Markers*, 33:4 23-431, 2018 (doi: 10.1177/1724600818776838). \*

84. A. Vitale, F. Farinati, G. Noaro, P. Burra, T.M. Pawlik, L. Bucci, E.G. Giannini, C. Faggiano, F. Ciccarese, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, G. Cabibbo, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati-Baroni, F.G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, F. Fornari, M. Marignani, S. Vicari, E. Bortolini, R. Cozzolongo, A. Grasso, C. Aliberti, M. Bernardi, A.C. Frigo, M. Borzio, F. Trevisani, U. Cillo; Italian Liver Cancer (ITA.LI.CA) group. Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study. *Hepatology*, 68:1232-1244, 2018 (doi: 10.1002/hep.30185). \*
85. S. De Lorenzo, F. Tovoli, M. A. Barbera, F. Garuti, A. Palloni, G. Frega, I. Garajova, A. Rizzo, F. Trevisani, G. Brandi. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept". *Sci. Rep.*, 8: 9997, 2018 (doi: 10.1038/s41598-018-28337-6). \*
86. C. Rognoni, O. Ciani, S. Sommariva, I.e Bargellini, S. Bhoori, R. Cioni, A. Facciorusso, R.a Golfieri, A. Gramenzi, V. Mazzaferro, C. Mosconi, F. Ponziani, R. Sacco, F. Trevisani, R. Tarricone. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. *BMC Cancer*, 18: 715, 2018 (doi: 10.1186/s12885-018-4636-7). \*
87. M. Guarino, L. Viganò, F. Romana Ponziani, E.G. Giannini, Q. Lai, F. Morisco, on behalf of the Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies" of the Italian Association for the Study of the Liver. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: literature review and risk analysis. *Dig. Liver Dis.*, 50: 1105-1114, 2018 (doi: 10.1016/j.dld.2018.08.0012018). \*

## 2019

88. A. Vitale, F. Farinati, M. Borzio, F. Trevisani, U. Cillo. The critical issue of restaging patients with hepatocellular carcinoma: Reply. *Hepatology*, 69, 465, 2019 (lettera). \*
89. D. Pinato, E. Allara, T.Y. Chen, F. Trevisani, Minguéz B, M. Zoli, M. Harris, A. Dalla Pria, N. Merchante, H. Platt, M. Jain, E. Caturelli, L. Kikuchi, J. Pineda, M. Nelson, F. Farinati, G.L. Rapaccini, A. Aytaman, M. Yin, C.K. Tan, M. Bower, E.G. Giannini, N. Bräu; Liver Cancer in HIV and ITA.LI.CA Study Groups. The influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multi-cohort study. *J. Clin. Oncol.*, 37: 296-304, 2019 (doi: 10.1200/JCO.18.00885). \*
90. R. Golfieri, I. Bargellini, C. Spreafico, F. Trevisani. Patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: Time for a subclassification. *Liver Cancer*, 8: 78-91, 2019 (doi: 10.1159/000489791). \*
91. F. Trevisani, F. Garuti, A. Neri. Alpha-fetoprotein for diagnosis, prognosis and transplant selection. *Semin. Liver Dis.*, 39: 163–177, 2019 (doi: 10.1055/s-0039-1677768). \*
92. G. Cabibbo, C. Celsa, V. Calvaruso, S. Petta, I. Cacciola, M.R. Cannavò, S. Madonia, M. Rossi, B. Magro, F. Rini, M. Distefano, L. Larocca, T. Prestileo, G. Malizia, G. Bertino, F. Benanti, A. Licata, I. Scalisi, G. Mazzola, M.A. Di Rosolini, G. Alaimo, A. Averna, F. Cartabellotta, N. Alessi, S. Guastella, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, F. Trevisani, A. Craxì, V. Di Marco, C. Cammà; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV), Italian Liver Cancer (ITA.LI.CA.) Group. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J. Hepatol.*, 71: 265-273, 2019 (doi: 10.1016/j.jhep.2019.03.027). \*

93. M. Ravaioli, F. Odaldi, A. Cucchetti, F. Trevisani, F. Piscaglia, V. De Pace, V. Bertuzzo, F. Neri, R. Golfieri, A. Capelli, A. D'Errico, M. Cescon, M. Del Gaudio, G. Fallani, A. Siniscalchi, M. C. Morelli, F.a Ciccarese, M. Di Marco, F. Farinati, E.G. Giannini, A. D. Pinna. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. *Sci. Rep.*, 9: 3781, 2019 (doi: 10.1038/s41598-019-40543-4). \*
94. E.G. Giannini, F. Trevisani. Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein. *Hepatobiliary Surg. Nutr.*, 8: 515-518, 2019 (doi: 10.21037/hbsn.2019.04.19). \*
95. G. Galati, M. Muley, M. Vigano, M. Iavarone, A. Vitale, C. Dell'Unto, Q. Lai, G. Cabibbo, R. Sacco, E. Villa, F. Trevisani. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. *Expert Opin. Drug Saf.*, 18: 603-610, 2019 (doi.org/10.1080/14740338.2019.1617272). \*
96. E. G. Giannini, A. Aglitti, M. Borzio, M. Gambato, M. Guarino, M. Iavarone, Q. Lai, G. Sandri, F. Melandro, F. Morisco, F. R. Ponziani, M. Rendina, F. P. Russo, R. Sacco, M. Viganò, A. Vitale, F. Trevisani. Overview of immunotherapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immunotherapy in clinical practice. *Cancers* 2019 Oct 30;11(11). pii: E1689 (doi: 10.3390/cancers11111689). \*
97. A. Vitale, F. Farinati, T.M. Pawlik, A.C. Frigo, E.G. Giannini, L. Napoli, F. Ciccarese, G.L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, G. Cabibbo, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati-Baroni, F.G. Foschi, G. Missale, A. Masotto, G. Nardone, A. Colecchia, M. Bernardi, F. Trevisani, U. Cillo. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. *Liver Int.*, 39:1478-1489, 2019 (doi: 10.1111/liv.14154).
98. Q. Lai, Vitale A, T.M. Manzia, F.G. Foschi, G.B. Levi Sandri, M. Gambato, F. Melandro, F.P. Russo, L. Miele, L. Viganò, P. Burra, E.G. Giannini; HCC Special Interest Group, Associazione Italiana per lo Studio del Fegato (AISF). Platelets and hepatocellular cancer: bridging the bench to the clinics. *Cancers*, Oct 15;11(10). pii: E1568, oct. 2019 (doi: 10.3390/cancers11101568). \*

## 2020

99. N. Alkhoury, M. Imawari, N. Izumi, Y. Osaki, T. Ochiai, T. Kano, R. Bentley, F. Trevisani. Lusutrombopag is efficacious for thrombocytopenia in hepatocellular carcinoma: integrated analysis of two phase 3 trials. *Clin J Gastroenterol.* 20; S1542-3565 (20) 30344-X, 2020 (doi: 10.1016/j.cgh.2020.032). \*
- 100.A. Vitale, F. Trevisani, F. Farinati, U. Cillo. Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy. *Hepatology* 2020 Feb 16 (doi: 10.1002/hep.31187). Online ahead of print. \*
- 101.C. Mosconi, A.G. Gramenzi, M. Biselli, A. Cappelli, A. Bruno, C. De Benedittis, A. Cucchetti, F. Modestino, G. Peta, G. Bianchi, F. Trevisani, R. Golfieri. Survival and tolerability of trans-arterial chemoembolization in greater versus less than 70 years of age patients with unresectable hepatocellular carcinoma: a propensity score analysis. *Cardiovasc. Intervent. Radiol.* 2020; 43: 1015-1024. (doi: 10.1007/s00270-020-02451-3). \*